Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N.ClH |
Molecular Weight | 261.79 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)[C@H](CC1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=VKIHKZMKDNVEIK-PKLMIRHRSA-N
InChI=1S/C16H19N.ClH/c1-17(2)16(15-11-7-4-8-12-15)13-14-9-5-3-6-10-14;/h3-12,16H,13H2,1-2H3;1H/t16-;/m1./s1
Molecular Formula | C16H19N |
Molecular Weight | 225.3288 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2571492Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16991666 | https://www.ncbi.nlm.nih.gov/pubmed/26276083 | https://www.ncbi.nlm.nih.gov/pubmed/1417455
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2571492
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16991666 | https://www.ncbi.nlm.nih.gov/pubmed/26276083 | https://www.ncbi.nlm.nih.gov/pubmed/1417455
Lefetamine (L-SPA; L-1,2-diphenyl-l-dimethylaminoethane hydrochloride) is a synthetic compound with analgesic and anti-inflammatory action, introduced in clinical practice in Italy and Japan as ‘Santenol’. Santenol is available for oral (50 mg tablets1 and intramuscular (60 mg vials containing also lidocainel use. Animal studies have shown an analgesic effect and changes in EEG activity and O2 consumption of the nervous tissue. Lefetamine may be an opioid partial agonist. Lefetamine was first marketed in the 1940s as an opioid analgesic. Since withdrawal symptoms were observed during treatment, it became a controlled substance.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2571492 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2571492
In clinical trial patients were assigned to lefetamine treatment programme.
After stabilization on admission with a sufficient lefetamine dosage (mean 450 mg/day) five of them underwent a progressive lefetamine withdrawal with increasing sedative-antimanic therapy (neuroleptics such as levopromazine, chlorpromazine or sodium valproatel.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26276083
Incubation mixtures (final volume: 50 mkL) consisted of 90 mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate dehydrogenase, 200 U/mL superoxide dismutase, liver enzymes and the LEFETAMINE (up to 1000mkM), diluted in the phosphate buffer. Reactions were started by addition of the ice-cold microsomes and
stopped with 50 mkL of an ice-cold mixture of acetonitrile, containing the IS (diphenhydramine, 10 mkM). The solutions were centrifuged for 2 min at 14,000 x g, 50 mkL of the supernatant was transferred to an autosampler vial and injected onto the LC–MSn system.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:27 GMT 2023
by
admin
on
Fri Dec 15 15:17:27 GMT 2023
|
Record UNII |
XYT5RKF8JA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
1635
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
443969
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
m1201
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
14148-99-3
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106355
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
24361-76-0
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
ALTERNATIVE | |||
|
XYT5RKF8JA
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
100000086644
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
DTXSID00931103
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY | |||
|
SUB02884MIG
Created by
admin on Fri Dec 15 15:17:27 GMT 2023 , Edited by admin on Fri Dec 15 15:17:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |